Opthea to Participate in Citi 2024 Global Healthcare Conference
Opthea to Participate in Citi 2024 Global Healthcare Conference
MELBOURNE, Australia and PRINCETON, N.J., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, "Opthea", the "Company"), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that Fred Guerard, PharmD, Chief Executive Officer, will host one-on-one meetings with investors and participate in a panel presentation during the Citi 2024 Global Healthcare Conference on December 5, 2024 in Miami, Florida.
MELBOURNE, Australia and PRINCETON, N.J., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPt, "Opthea", the "Company"), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that Fred Guerard, PharmD, Chief Executive Officer, will host one-on-one meetings with investors and participate in a panel presentation during the Citi 2024 Global Healthcare Conference on December 5, 2024 in Miami, Florida.
Details are as follows:
详细信息如下:
| Panel: | Eyes Wide Open on Ophthalmology |
| Presenter: | Frederic Guerard, PharmD, CEO, Opthea |
| Date: | Thursday, December 5, 2024, 1:45 PM ET |
| Panel: | Eyes Wide Open on Ophthalmology |
| 报告人： | Frederic Guerard，药学博士，CEO，opthea |
| 日期： | 2024年12月5日，星期四，东部时间下午1:45 |
The webcast will be accessible on the "Events & Presentations" section of the Company's website at
网络直播将可以在公司网站的“活动与演示”部分访问
About Opthea
关于Opthea
Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Opthea (ASX/纳斯达克:OPT)是一家生物制药公司，致力于开发新型疗法来解决治疗高发性和进行性视网膜疾病的未满足需求，包括湿性年龄相关性黄斑变性（湿AMD）和糖尿病性黄斑水肿（DME）。
Opthea's lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A therapies to improve overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone.
opthea的先导产品候选药物sozinibercept正在两项完全招募完成的关键第3期临床试验（COASt，NCT04757636和ShORe，NCT04757610）中接受评估，用于与标准关怀抗VEGF-A疗法结合使用，以改善整体疗效并提供比单独使用标准关怀抗VEGF-A药物更卓越的视力收益。
To learn more, visit our website at and follow us on X and LinkedIn.
欲了解更多信息，请访问我们的网站，关注我们的X和LinkedIn。
Authorized for release to ASX by Frederic Guerard, PharmD, CEO
由Frederic Guerard，PharmD，首席执行官授权发布至ASX
Investor Inquiries
PJ Kelleher
LifeSci Advisors, LLC
Email: pkelleher@lifesciadvisors.com
Phone: 617-430-7579
投资者查询
PJ Kelleher
LifeSci Advisors, LLC
电子邮件：pkelleher@lifesciadvisors.com
电话:617-430-7579
Media Inquiries
Silvana Guerci-Lena
NorthStream Global Partners
Email: silvana@nsgpllc.com
媒体咨询
Silvana Guerci-Lena
NorthStream全球合作伙伴
电子邮件：silvana@nsgpllc.com
Join our email database to receive program updates:
Tel: +61 (0) 3 9826 0399, Email: info@opthea.com Web:
Source: Opthea Limited
加入我们的电子邮件数据库，以获得项目更新信息：
电话：+61 (0) 3 9826 0399，电子邮件：info@opthea.com网址：
来源：opthea有限公司
